17.05.2005 12:34:00

REMINDER/Phase Forward to Drive Industry Dialog at Annual Bio-IT World

REMINDER/Phase Forward to Drive Industry Dialog at Annual Bio-IT World Conference + Expo; Paul Bleicher, M.D., Ph.D, to Address Safety Surveillance in Clinical Trials and Provide Insight on eClinical Vendor Strategies and Markets


    Business Editors/High-Tech Editors/Medical Editors
    BioITWorld Boston 2005
    Booth 608
    REMINDER

    BOSTON--(BUSINESS WIRE)--May 17, 2005--Phase Forward (NASDAQ: PFWD)

Who: Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety

What: Bio-IT World 2005 Conference + Expo

When: Tuesday, May 17 through Thursday, May 19, 2005

Where: Hynes Convention Center, Boston, Massachusetts
    Bio-IT World Conference + Expo demonstrates how technology is transforming life sciences throughout discovery and development processes. The event is designed for life science professionals seeking to evaluate and understand advanced solutions that generate, collect, and analyze the flood of information produced by the life sciences industry. Visionaries from the biotechnology, pharmaceutical, healthcare, academic, and government markets convene to learn how the latest tools and best practices will help revolutionize health, environment, and society.
    As part of this year's conference, Phase Forward's Chairman and Founder, Paul Bleicher, M.D., Ph.D, will provide his insight and experience as part of the following panel discussions:

    -- "Safety Surveillance in Clinical Trials - New Technologies to
    Assess Safety"

    The panel discussion will highlight ways the biopharmaceutical industry can assess the safety of products and ensure the safety of patients who use them. The session will include presentations from representatives of the pharmaceutical industry, press, and technology/service providers, followed by Q&A. The goal of this panel is to present a broad picture of key safety issues and provide clarification of the technologies available for assessing them. The panel will be moderated by Rebecca D. Kush, PhD, President, Clinical Data Interchange Standards Consortium (CDISC). Wednesday, May 18, from 10:45 AM - 11:30 AM.

    -- "eClinical Vendor Panel Discussion"

    Following up last year's session, Paul Bleicher will join other senior executives who will present their views on current and projected market conditions, challenges, and opportunities facing eClinical technology vendors. The panel will be moderated by Jerald S. Schindler, DrPH, Asst. VP, Global Biostatistics & Clinical Technology, Wyeth Research. Wednesday, May 18, from 1:00 PM - 2:30 PM.

    Attendees are also invited to visit Phase Forward at Booth #608 to learn more about the company's clinical data management solutions.
    For media inquiries, please contact Brian Gendron of SHIFT Communications at 617-681-1226.

    About Phase Forward

    Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company helps pharmaceutical, biotechnology, and medical device companies bring needed drugs and therapies to market faster and more safely. Phase Forward offers proven solutions in electronic data capture (EDC), clinical data management (CDM), and adverse event reporting (AER). Phase Forward products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 220 organizations worldwide including: AstraZeneca, Biogen Idec, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, GlaxoSmithKline, Guidant, Procter & Gamble, Quintiles, Sanofi-Aventis, Schering-Plough Research Institute, and Serono. Additional information about Phase Forward is available at www.phaseforward.com.

--30--KC/bo*

CONTACT: SHIFT Communications Brian Gendron, 617-681-1226

KEYWORD: MASSACHUSETTS TRACK INDUSTRY KEYWORD: HARDWARE BIOTECHNOLOGY SOFTWARE INTERNET E-COMMERCE REMINDER TRADESHOW SOURCE: Phase Forward

Copyright Business Wire 2005

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Oracle Corp.mehr Analysen

27.01.25 Oracle Buy Jefferies & Company Inc.
03.01.25 Oracle Sector Perform RBC Capital Markets
10.12.24 Oracle Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
10.12.24 Oracle Sector Perform RBC Capital Markets
10.12.24 Oracle Neutral JP Morgan Chase & Co.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Oracle Corp. 163,92 -0,28% Oracle Corp.

Indizes in diesem Artikel

NASDAQ Comp. 19 391,96 -1,20%